Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial.
Health-related quality-of-life
Latent class analysis
Medications for opioid use disorder
Opioid use disorder
Regression mixture modeling
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
21
04
2020
revised:
26
07
2020
accepted:
28
07
2020
pubmed:
11
8
2020
medline:
13
3
2021
entrez:
11
8
2020
Statut:
ppublish
Résumé
To examine the health-related quality-of-life (HRQoL) of persons with opioid use disorder (OUD) seeking treatment in an inpatient detoxification or short-term residential setting; continuing treatment as outpatients. We conducted a secondary analysis of data from a clinical trial (N = 508) where participants were randomized to extended-release naltrexone or buprenorphine-naloxone for the prevention of opioid relapse. We used a generalized structural equation regression mixture model to identify associations of HRQoL (EQ-5D) trajectories, including latent characteristics, over the 24-week trial and 36-week follow-up period, among participants who reported HRQoL beyond baseline. This novel framework accounted for baseline and time-varying characteristics, while simultaneously identifying latent classes. We identified two subpopulations: HRQoL "pharmacotherapy responsive" (82.3 %) and HRQoL "characteristic sensitive" (17.7 %). The pharmacotherapy responsive subpopulation was characterized by a shortterm HRQoL improvement and then stable HRQoL over time, and by a positive association between HRQoL and receiving pharmacotherapy in the past 30 days. The characteristic sensitive subpopulation was characterized by an initial improvement in HRQoL with a gradual decline over time, and no significant HRQoL response to pharmacotherapy. HRQoL changes over time in this subpopulation were more influenced by baseline demographic, socioeconomic, and psychosocial characteristics. Our findings suggest that while HRQoL may be improved and sustained through targeted efforts to promote use of pharmacotherapy for many persons with OUD, an identifiable subpopulation may require additional services that address socioeconomic and psychosocial issues to achieve HRQoL benefits. Our analysis provides insight for improving individualized care for persons with opioid use disorder seeking treatment.
Identifiants
pubmed: 32777692
pii: S0376-8716(20)30386-0
doi: 10.1016/j.drugalcdep.2020.108221
pmc: PMC7502461
mid: NIHMS1620105
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Buprenorphine, Naloxone Drug Combination
0
Naltrexone
5S6W795CQM
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
108221Subventions
Organisme : NIDA NIH HHS
ID : U10 DA013035
Pays : United States
Organisme : NIDA NIH HHS
ID : HHSN271201200017C
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA040500
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA035808
Pays : United States
Organisme : NIDA NIH HHS
ID : U10 DA013714
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA013035
Pays : United States
Organisme : NIDA NIH HHS
ID : K24 DA022412
Pays : United States
Organisme : NIDA NIH HHS
ID : U10 DA015833
Pays : United States
Organisme : NIDA NIH HHS
ID : U10 DA013720
Pays : United States
Organisme : NIDA NIH HHS
ID : U10 DA013046
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA046721
Pays : United States
Organisme : NIDA NIH HHS
ID : HHSN271201500065C
Pays : United States
Organisme : NIDA NIH HHS
ID : U10 DA013732
Pays : United States
Organisme : NIDA NIH HHS
ID : U10 DA013045
Pays : United States
Organisme : NIDA NIH HHS
ID : U10 DA013034
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
J Subst Abuse Treat. 2020 Mar;112S:18-27
pubmed: 32220406
Soc Sci Med. 1999 Jun;48(11):1507-15
pubmed: 10400253
Drug Alcohol Depend. 2014 Sep 1;142:46-55
pubmed: 25015687
Ann Intern Med. 2019 Jan 15;170(2):90-98
pubmed: 30557443
Drug Alcohol Depend. 2011 Nov 1;118(2-3):259-64
pubmed: 21546173
Drug Alcohol Depend. 2019 Dec 1;205:107649
pubmed: 31704382
Annu Rev Clin Psychol. 2010;6:109-38
pubmed: 20192788
J Acquir Immune Defic Syndr. 2015 Nov 1;70(3):304-10
pubmed: 26218410
J Subst Abuse Treat. 2016 Aug;67:30-7
pubmed: 27296659
Int J Drug Policy. 2010 Sep;21(5):364-80
pubmed: 20172706
Alcohol Clin Exp Res. 2000 Jun;24(6):882-91
pubmed: 10888079
J Subst Abuse Treat. 2017 May;76:88-93
pubmed: 28190543
J Subst Abuse Treat. 1992;9(3):199-213
pubmed: 1334156
Contemp Clin Trials. 2016 Sep;50:253-64
pubmed: 27521809
Struct Equ Modeling. 2016;23(4):601-614
pubmed: 31588168
N Engl J Med. 2009 Aug 20;361(8):777-86
pubmed: 19692689
Lancet. 2018 Jan 27;391(10118):309-318
pubmed: 29150198
Drug Alcohol Depend. 2015 Dec 1;157:121-8
pubmed: 26511766
Med Care. 2020 Apr;58(4):e23-e30
pubmed: 31764479
Osteoarthritis Cartilage. 2015 Dec;23(12):2141-2149
pubmed: 26187575
Addiction. 2016 Apr;111(4):675-84
pubmed: 26498740
Transl Behav Med. 2016 Jun;6(2):228-35
pubmed: 27356993
Front Psychol. 2018 Feb 22;9:130
pubmed: 29520242
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Drug Alcohol Depend. 2010 Aug 1;110(3):208-20
pubmed: 20395074
Int J Drug Policy. 2013 Jul;24(4):342-50
pubmed: 23127664
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
Struct Equ Modeling. 2013 Oct 1;20(4):640-657
pubmed: 24489457